0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2001;285(19):2415. doi:10.1001/jama.285.19.2415.
Text Size: A A A
Published online

INFANT BREASTFEEDING AND RISK OF OVERWEIGHT IN CHILDHOOD

Some evidence suggests that breastfeeding in infancy protects against overweight later in life. In this analysis of data from the Third National Health and Nutrition Examination Survey, Hediger and colleaguesArticle found that among children aged 3 to 5 years, the risk of having a body mass index (BMI) between the 85th and 94th percentiles (at risk of overweight) was reduced among children ever breastfed compared with those who were never breastfed. However, no difference in the risk of overweight (BMI in the 95th percentile or higher) was observed, and there was no clear dose-dependent effect of the duration of exclusive breastfeeding on either weight outcome. To assess whether breastfeeding in infancy is associated with a reduced risk of overweight in adolescence, Gillman and colleaguesArticle analyzed survey data from children in the Growing Up Today Study, a study of the sons and daughters aged 9 to 14 years of women participating in the Nurses' Health Study II. Children who had been mostly or only breastfed, or breastfed for longer periods, had a reduced risk of being overweight at age 9 to 14 years. In an editorial, DietzArticle considers possible explanations for the disparity in the findings of these 2 studies and mechanisms by which breastfeeding may protect against overweight.

BENEFIT OF EPTIFIBATIDE PERSISTS 6 MONTHS AFTER STENTING

In the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial, patients scheduled to undergo nonurgent coronary stent implantation who received eptifibatide, a competitive inhibitor of platelet glycoprotein IIb/IIIa, had significantly better outcomes 30 days after the percutaneous coronary intervention than patients who received placebo. In this 6-month follow-up study, O'Shea and colleagues report that the primary composite end point, rates of death or myocardial infarction (MI), continued to be significantly lower in the eptifibatide group. Composite rates of death, MI, or target vessel revascularization were also lower in the eptifibatide group, but there was no significant difference in 6-month mortality alone.

See Article

EFFECTIVENESS OF TREATMENTS FOR HALLUX VALGUS

Treatments for hallux valgus include conservative management with orthoses and surgical correction. Torkki and colleagues compared these treatments with no treatment (control group) among patients with a painful bunion and a hallux valgus angle of 35° or less. At 6 months, pain intensity during walking was less in the 2 active treatment groups than in the control group. At 12 months, however, there was no significant difference in pain intensity in the orthoses and control groups, whereas pain intensity continued to decrease in the surgery group. Number of painful days, cosmetic disturbance, and footwear problems were lowest in the surgical group, and satisfaction with treatment and patient global assessment were better than in the other 2 groups.

See Article

BIOMARKERS PREDICTIVE OF PERIPHERAL ARTERIAL DISEASE

Using data from the Physicians' Health Study, a prospective cohort of healthy male US physicians aged 40 to 84 years at baseline, Ridker and colleagues conducted a nested case-control study to evaluate biomarkers as risk factors for the development of symptomatic peripheral arterial disease (PAD). Lipid biomarkers included total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, total cholesterol to HDL-C ratio, triglycerides, lipoprotein(a), and apolipoproteins A-1 and B-100. Nonlipid biomarkers included homocysteine and 2 inflammatory markers, fibrinogen and C-reactive protein. In multivariable analyses, total cholesterol to HDL-C ratio was the strongest lipid predictor of PAD; and C-reactive protein, the strongest nonlipid predictor.

See Article

A PIECE OF MY MIND

"There was a time when I could not imagine life without practicing medicine; now I consider other choices." From "Visiting the Sadness."

See Article

MEDICAL NEWS & PERSPECTIVES

Successful treatment of many children with cancer has led to a need to find and address factors contributing to the negative consequences that can occur later in their lives.

See Article

ADULT TREATMENT PANEL III REPORT

The third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Article emphasizes primary prevention of coronary heart disease in persons with multiple risk factors and early and aggressive lipid-lowering therapy for those at highest risk.Article

THE RATIONAL CLINICAL EXAMINATION

How to assess whether a patient with a stated penicillin allergy is truly allergic to penicillin.

See Article

JAMA PATIENT PAGE

For your patients: Information about cholesterol and atherosclerosis.

See Article

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.